[ad_1]
A Centers for Disease Control and Prevention (CDC) advisory committee is due to meet on Thursday to review data regarding cases of the rare syndrome in people who have received a COVID-19 vaccine.
The Advisory Committee on Immunization Practices, a panel of medical and public health experts who make recommendations on vaccinations, will hear from officials about the onset of Guillain-Barré syndrome in Americans who have received the COVID vaccine -19 from Johnson & Johnson, according to a draft agenda.
Presenters include Dr Narayan Nair, an official with the Food and Drug Administration, Dr Nicola Klein of Kaiser Permanente Northern California and panel member Dr Grace Lee, who chairs the vaccine safety technical subgroup of the panel.
Nair will review data from the Vaccine Adverse Event Reporting System, to which anyone can submit adverse event reports and which is used by federal officials to detect such post-vaccination events. Klein will discuss data from the Vaccine Safety Datalink, which uses information from nine healthcare groups, including Kaiser Permanente. Lee will present the data from the subgroup she chairs.
After a public discussion, Dr. Hannah Rosenblum, a CDC official, will discuss the benefits versus the risks of getting the Johnson & Johnson jab.
Guillain-Barré syndrome (CSS) is a rare neurological disease. Afflicted people have their immune system mistakenly attacking part of their nervous system. The results can include muscle weakness and, in some cases, paralysis. Most people who get the syndrome can make a full recovery.
More than 900 reports of disorders occurring in people who have been injected with COVID-19 have been reported to the Vaccine Adverse Event Reporting System, according to a review of Epoch Times data on July 21. Seven of those cases resulted in death, while 134 others caused permanent disability, according to reports.
The Food and Drug Administration said last week that “the available evidence suggests an association between the Janssen vaccine and an increased risk of GBS,” although the evidence has not established a causal relationship. Janssen is a subsidiary of Johnson & Johnson; no similar signal has been linked to the Moderna or Pfizer shots.
A spokesperson for the CDC told The Epoch Times the agency is monitoring GBS reports.
Most cases in America have been seen around two weeks after vaccination in men 50 years of age and older.
Regulators believe that the known and potential benefits of the Johnson & Johnson jab “clearly outweigh” the known and potential risks.
Yet the administration added a warning about GBS to an information sheet for people receiving and administering the vaccine.
The July 22 meeting will be another in a series of safety data reviews as the number of adverse events related to COVID-19 vaccines increases. COVID-19 is the disease caused by the virus of the CCP (Chinese Communist Party).
Officials met last month to review data on cases of post-vaccination heart inflammation, finding that cases were well above the expected rate among young men. The CDC’s advice did not adjust its recommendations on vaccinating young people, although the FDA added a warning about the risk of developing inflammation after receiving the Moderna or Pfizer vaccine.
Most cases started after the second injection in a two-dose regimen.
Johnson & Johnson’s vaccine was previously linked to rare blood clots and low levels of blood platelets, triggering an almost nationwide halt in the use of the vaccine. But the CDC’s advisory committee recommended in a 10-4 vote that the break in use be lifted after reviewing the data. On the agency’s website, it is stated that recent reports “indicate a plausible cause-and-effect relationship” between the condition of the blood clot and the vaccine.
Jack Phillips contributed to this report.
[ad_2]
Source link